8-K: Vycor Medical Reports Strong 2025 Revenue Growth

Vycor Medical, Inc. announced its financial results for the year ended December 31, 2025, reporting an 18% increase in Vycor Medical division revenues and a return to operating profit.

Summary

• Total revenue for the year ended December 31, 2025, was $1,863,400, an increase of 17% over 2024.
• The Vycor Medical division (VBAS) generated revenue of $1,796,070, an 18% increase over 2024, with most growth from international markets and continued US sales.
• The NovaVision division, which remains in development, generated revenues of $67,330, an 8% decrease from 2024.
• The company reported a GAAP operating profit of $33,900 for 2025, a significant improvement from an operating loss of $(9,145) in 2024.
• Non-GAAP operating profit increased by $64,333 to $145,881 in 2025, compared to $81,548 in 2024.
• Gross profit for 2025 was $1,561,107, an 11% increase over 2024, with a gross margin of 83% (down from 89% in 2024).
• Seven new peer-reviewed studies on the ViewSite Brain Access System (VBAS) were published in 2025, bringing the total to 50, highlighting clinical advantages.
• A new clinical study validated NovaVision's NeuroEyeCoach for effective home-based use, aligning with global healthcare trends.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to significant revenue growth in the core medical device division, a return to operating profitability, and strong clinical validation for both product lines, despite the continued net loss and slight margin compression.

Positives

• Total revenue increased by 17% to $1,863,400 for the year ended December 31, 2025.
• Vycor Medical division revenue increased by 18% to $1,796,070, driven by strong international growth and continued US sales.
• The company achieved a GAAP operating profit of $33,900 in 2025, a turnaround from an operating loss of $(9,145) in 2024.
• Non-GAAP operating profit significantly increased by $64,333 to $145,881.
• Net loss available to common stockholders improved to $(396,796) from $(431,570) in 2024.
• The ViewSite Brain Access System (VBAS) now has 50 peer-reviewed clinical papers, with 7 new studies in 2025 highlighting reduced brain tissue damage, improved patient outcomes, and reduced hospital stay.
• NovaVision's NeuroEyeCoach program was validated for effective home-based use, aligning with the global drive for digital healthcare technologies.

Negatives

• NovaVision division revenue decreased by 8% to $67,330 for the year ended December 31, 2025.
• Gross margin for the Vycor Medical division decreased to 83% in 2025 from 89% in 2024, attributed to validation, shipping, higher manufacturing costs, and a higher international sales mix.
• The company still reported a GAAP net loss of $(396,796) and a non-GAAP net loss of $(284,815).
• Significant preferred stock dividends of $(324,370) continued to impact net loss available to common stockholders.
• NovaVision therapies 'still require significant development to allow them to successfully address their market potential'.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors which could cause actual results, performance, or achievements to differ from those expressed or implied.
• Risks, uncertainties, and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission.

Future Outlook

The company's strategy includes continued international growth for its Vycor Medical division. NovaVision's NeuroEyeCoach is positioned to benefit from the significant global drive towards digital technologies in home healthcare settings, although the NovaVision therapies still require significant development to fully address their market potential.

Management Comments

• Management believes that non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of ongoing operating results and trends, compared with historical results.
• Management states that the non-GAAP presentation is consistent with the measures used to evaluate the performance of ongoing operating results against prior periods and internally developed targets.

Industry Context

StockSavvy.ai notes that Vycor Medical's focus on international expansion for its VBAS system aligns with a broader trend in medical device companies seeking growth in emerging markets. The validation of home-based digital therapies like NeuroEyeCoach positions NovaVision favorably within the rapidly expanding digital health and telehealth sectors, which are seeing increased adoption globally, especially post-pandemic.

Comparison to Industry Standards

• The VBAS system, with 50 peer-reviewed studies, demonstrates strong clinical validation, comparable to leading medical devices that require extensive evidence for market adoption in specialized surgical fields.
• NovaVision's NeuroEyeCoach, supported by a 296-patient study, represents a significant data point in the neuro-visual space, potentially positioning it as a leader in evidence-based digital rehabilitation, similar to how other digital therapeutics like Pear Therapeutics' reSET-O have gained traction with robust clinical backing.
• The 83% gross margin for Vycor Medical, while slightly down from the previous year, remains robust for a medical device company, often exceeding the average for general manufacturing but potentially lower than some high-margin software-as-a-service (SaaS) medical solutions.

Related Party Transactions

• Interest expense: Related Party of $(50,283) for the year ended December 31, 2025.

Stakeholder Impact

• Shareholders: Improved operating profit and reduced net loss could be positive, but continued net losses and significant preferred stock dividends might concern common shareholders.
• Customers (Patients/Hospitals): Continued clinical validation and expanded international reach of VBAS, along with validated home-based NovaVision therapies, suggest improved access to effective medical solutions.
• Employees: Continued growth and development in both divisions could indicate job stability and potential for expansion.

Next Steps

• Continued development for NovaVision therapies to address their market potential.
• Further international expansion for the Vycor Medical division.

Key Dates

Recommendation

While Vycor Medical demonstrated strong revenue growth in its core VBAS division and achieved operating profitability, the company still reports a net loss, and the NovaVision division, though clinically validated, remains in development and saw a revenue decline. The significant preferred stock dividends also impact common shareholder value. The positive operational momentum warrants a 'hold' as the company works towards sustainable overall profitability and fully develops its NovaVision segment.

Keywords

Vycor Medical, VBAS, ViewSite Brain Access System, NovaVision, NeuroEyeCoach, Visual Restoration Therapy, neurosurgery, visual disorders, stroke, brain injury, medical devices, financial results, earnings, revenue, operating profit, GAAP, non-GAAP